8-K: Varex Q3 FY2025: Revenue Beats Guidance Amid Goodwill Impairment

Varex Imaging Corporation reported third-quarter fiscal year 2025 revenues of $203 million, exceeding guidance, despite a significant GAAP net loss driven by a goodwill impairment charge.

Summary

• Third quarter fiscal year 2025 revenues were $203 million, surpassing the high-end of guidance.
• GAAP net loss was $(2.15) per diluted share, primarily due to a $93.9 million goodwill impairment charge.
• Non-GAAP net earnings were $0.18 per diluted share, an increase from $0.14 in the third quarter of fiscal year 2024.
• Cash flow from operations for the quarter was $8 million.
• Medical segment revenue decreased 4% year-over-year to $142 million.
• Industrial segment revenue increased 1% year-over-year to $61 million, demonstrating continued strength.
• Non-GAAP gross margin improved to 34% compared to 32% in the third quarter of fiscal year 2024.
• Cash, cash equivalents, and marketable securities stood at $153 million at quarter-end, down from $226 million in the prior quarter due to the paydown of Convertible Notes.

Sentiment

Score: 5

Explanation: While Varex exceeded revenue guidance and improved non-GAAP EPS, the significant GAAP net loss of $(89.1) million, primarily due to a $93.9 million goodwill impairment, and a sequential decrease in cash, present a mixed financial picture. The positive performance in the Industrial segment and better-than-expected China Medical revenue are offset by overall revenue decline and the substantial impairment charge.

Positives

• Q3 FY2025 revenue of $203 million exceeded the high-end of guidance.
• Industrial segment revenue remained strong, growing 1% year-over-year to $61 million.
• Medical revenue in China performed better than expectations.
• Non-GAAP gross margin improved to 34% from 32% in Q3 FY2024.
• Non-GAAP EPS increased to $0.18 from $0.14 in Q3 FY2024.
• Continued adoption of systems in cargo inspection applications was noted.

Negatives

• Total revenues decreased 3% year-over-year to $203 million.
• Medical segment revenue declined 4% year-over-year to $142 million.
• A significant GAAP net loss of $(2.15) per diluted share was reported, primarily due to a $93.9 million goodwill impairment.
• Cash, cash equivalents, and marketable securities decreased sequentially from $226 million to $153 million.
• GAAP operating margin was (40)%, impacted by the goodwill impairment.
• Accumulated deficit increased to $(18.1) million from retained earnings of $64.4 million at September 27, 2024.

Risks

• Reduction in or loss of business from one or more limited OEM customers.
• Changes in import/export regulatory regimes, tariffs, trade wars, and national policies.
• Loss of business to, and an inability to effectively compete with, competitors.
• Pricing pressures and other factors that could result in market erosion or loss of customers.
• Failure to meet customers' needs and demands.
• Global, regional, and country-specific economic instability, shifting political environments, changing tax treatment, tariffs, trade wars, and other risks associated with international manufacturing, operations, and sales.
• Supply chain disruptions.
• Inability to maintain or defend intellectual property rights, and the high cost of protecting such rights and defending against infringement claims.
• Disruption of critical information systems or material breaches in the security of such systems.
• Non-compliance with regulations applicable to marketing, manufacturing, labeling, and distributing products, and delays in obtaining regulatory clearances or approvals.
• Limitations imposed by operating and financial restrictions of debt financing agreements.

Future Outlook

For the fourth quarter of fiscal year 2025, revenues are expected to be between $210 million and $230 million, with non-GAAP net earnings per diluted share projected to be between $0.10 and $0.30. Management anticipates a healthy demand environment for both Medical and Industrial segments, driving sales growth of approximately 3% for the full fiscal year 2025.

Management Comments

• "We are pleased to report that third quarter revenue of $203 million was above the high-end of our guidance." Sunny Sanyal, Chief Executive Officer.
• "Our Industrial segment remained strong in the quarter and Medical revenue in China was better than our expectations." Sunny Sanyal, Chief Executive Officer.
• "We are encouraged by the continued adoption of our systems in cargo inspection applications." Sunny Sanyal, Chief Executive Officer.
• "Additionally, we expect a healthy demand environment for both Medical and Industrial segments to drive sales growth of approximately 3% for fiscal year 2025." Sunny Sanyal, Chief Executive Officer.

Industry Context

Varex Imaging Corporation operates as a leading innovator, designer, and manufacturer of X-ray imaging components for medical, industrial, and security applications. The company's Q3 FY2025 performance reflects varied industry trends, with strength in industrial applications, particularly cargo inspection, and better-than-expected medical revenue in China. The overall decline in medical segment revenue suggests broader challenges in that market, while the industrial segment's growth indicates resilience and demand in security and logistics sectors.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks for a direct assessment.
• Varex positions itself as a leading innovator and manufacturer of X-ray imaging components, indicating a strong market position within its specialized niche.
• The company's 70+ year history of innovation suggests a mature and established presence in the X-ray imaging market, implying a competitive advantage in experience and technology.

Legal Proceedings

• Non-ordinary course litigation charges of $1.7 million for Q3 FY2025 and $5.1 million for the nine months ended July 4, 2025, were excluded from non-GAAP adjustments, indicating ongoing legal matters.

Stakeholder Impact

• Shareholders: Potential positive impact from revenue exceeding guidance and improved non-GAAP EPS, but negative impact from GAAP net loss due to goodwill impairment and sequential decrease in cash. Future sales growth guidance of 3% for FY2025 provides some stability.
• Employees: No direct impact on employees was mentioned in the filing, but the company employs approximately 2,300 people globally.
• Customers: Continued adoption of systems in cargo inspection applications indicates positive customer engagement. Medical segment revenue decline year-over-year suggests some challenges in that market, though China performed better than expected.
• Creditors: The paydown of Convertible Notes reduces debt obligations, which is a positive for creditors.

Next Steps

• Varex will conduct its earnings conference call on August 7, 2025, at 3:00 p.m. Mountain Time.
• The company expects to file its Form 10-Q for the third quarter of fiscal year 2025.

Key Dates

Recommendation

While Varex exceeded revenue guidance and showed improved non-GAAP EPS, the overall revenue decline year-over-year and a significant GAAP net loss due to a goodwill impairment present a mixed picture. The strength in the Industrial segment and better-than-expected China Medical revenue are positive, but the modest 3% full-year sales growth outlook suggests limited immediate upside. The paydown of convertible notes is a positive for the balance sheet. Given the mixed results and modest growth projections, a 'hold' recommendation is appropriate for investors to observe future performance and the impact of the goodwill impairment.

Keywords

Varex Imaging, VREX, Financial Results, Q3 2025, X-ray imaging, Medical imaging, Industrial imaging, Digital detectors, X-ray tubes, Cargo inspection, Earnings report, Goodwill impairment